作为具有潜在抗癌活性的选择性CDK2抑制剂的新型氨酸衍生物:设计,合成和生物评估
Alpesh Shah1, Nishith Teraiya2, Jignesh H Kamdar3
1BRCC Laboratory, Department of Chemistry, School of Science, RK University, Rajkot 360 020, Gujarat, India.
Bioorganic chemistry
|September 26, 2024
概括
新的 purin 类似物通过抑制 CDK2 (环素依赖激酶2) 来显示出它们作为抗癌剂的前景. 化合物5g和5i表现出显著的细胞毒性和选择性,需要进一步研究作为潜在的癌症治疗药物.
科学领域:
- 药用化学 医学化学
- 癌症生物学 癌症生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 氨酸类似物已经成为循环素依赖激酶2 (CDK2) 的抑制剂.
- CDK2是癌症治疗的潜在治疗标.
- 这项研究探讨了类类似物作为酶抑制剂的支架.
研究的目的:
- 设计,合成和评估新型 purin 类似物作为针对 CDK2.2 的抗癌剂.
- 评估合成化合物的体外抗癌活性和选择性.
主要方法:
- 进行了in silico分子对接和分子动力学模拟.
- 在优化反应条件下合成新型 purin 类比物.
- 使用NCI-60细胞系面板,细胞毒性试验和酶选择性试验进行抗癌评估.
- 西部斑点分析以确认目标参与和细胞亡/细胞循环停止试验.
主要成果:
- 在研究表明设计化合物对CDK2.2的高亲和力和稳定性.
- 化合物5g和5i对各种癌症细胞系表现出显著的抗癌活性,表现优于标准的seliciclib.
- 化合物5g和5i表现出对癌细胞的选择性细胞毒性超过正常细胞,并显示出强大的CDK2.2抑制.
- 化合物5g有效抑制了CDK2和下游标,诱导了细胞亡和G2/M细胞循环停止.
结论:
- 新型 purin 类似物已成功合成,并显示出强大的 CDK2 抑制活性.
- 化合物5g和5i由于其有效性,选择性和作用机制,显示出作为抗癌剂的显著潜力.
- 化合物5g需要在药理动力学/药理动力学 (PKPD) 研究中进一步调查潜在的治疗开发.
相关概念视频
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Cancer-Critical Genes II: Tumor Suppressor Genes
7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
Positive Regulator Molecules
5.4K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.4K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


